Abstract
Hypertension is a common chronic disease that particularly affects the elderly and can trigger several cardiovascular conditions. Although the treatment of hypertension has evolved in recent decades, many hypertensive patients still do not have properly controlled blood pressure. Accumulating evidence supports the hypothesis that DNA methylation plays an important role in regulating gene expression, altering the phenotype and function of the cardiovascular system. The present review highlights recent advances in research on DNA methylation in the development of hypertension. Several preclinical and clinical evidence show that methylation of different targets appears to be involved in hypertension. Studies of the involvement of DNA methylation have greatly improved our understanding of hypertension, but its use as a valid therapeutic target is still unknown. Further studies could help to bring to light the truth about gene therapy in hypertension.
Keywords: Blood pressure, cardiovascular disease, chronic disease, drug discovery, epigenomic, gene, phenotype.
Current Pharmaceutical Design
Title:Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility
Volume: 27 Issue: 35
Author(s): Priscila M. Joáo Job, Francislaine A. dos Reis Lívero and Arquimedes G. Junior*
Affiliation:
- Laboratory of Cardiovascular Pharmacology (LaFaC), Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, MS,Brazil
Keywords: Blood pressure, cardiovascular disease, chronic disease, drug discovery, epigenomic, gene, phenotype.
Abstract: Hypertension is a common chronic disease that particularly affects the elderly and can trigger several cardiovascular conditions. Although the treatment of hypertension has evolved in recent decades, many hypertensive patients still do not have properly controlled blood pressure. Accumulating evidence supports the hypothesis that DNA methylation plays an important role in regulating gene expression, altering the phenotype and function of the cardiovascular system. The present review highlights recent advances in research on DNA methylation in the development of hypertension. Several preclinical and clinical evidence show that methylation of different targets appears to be involved in hypertension. Studies of the involvement of DNA methylation have greatly improved our understanding of hypertension, but its use as a valid therapeutic target is still unknown. Further studies could help to bring to light the truth about gene therapy in hypertension.
Export Options
About this article
Cite this article as:
Joáo Job M. Priscila , dos Reis Lívero A. Francislaine and Junior G. Arquimedes*, Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility, Current Pharmaceutical Design 2021; 27 (35) . https://dx.doi.org/10.2174/1381612827666210322141703
DOI https://dx.doi.org/10.2174/1381612827666210322141703 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Pre-CKD- Do we Need Another Hero?
Current Vascular Pharmacology Comparative Studies on Hormonal Changes and Metabolic Syndrome in Perimenopausal and Premenopausal Igbo Women in Enugu Metropolis Nigeria: A Cross-sectional Study
Current Women`s Health Reviews Obesity in the Childhood: A Link to Adult Hypertension
Current Pharmaceutical Design Reduction of Sodium Intake is a Prerequisite for Preventing and Curing High Blood Pressure in Hypertensive Patients - Second Part: Guidelines
Current Hypertension Reviews Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews Resistin and Oxidative Stress in Non-Diabetic Obstructive Sleep Apnea Patients with Nocturnal Hypertension
Current Respiratory Medicine Reviews Intestinal Barrier Dysfunction Participates in the Pathophysiology of Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
Current Drug Therapy Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design Cardiovascular Disease in Masked Hypertension: Clinical Implications
Current Hypertension Reviews Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design Prevalence of HTN in Iran: Meta-analysis of Published Studies in 2004-2018
Current Hypertension Reviews C-Reactive Protein and Hypertension: Is there A Causal Relationship?
Current Pharmaceutical Design Blood Pressure and Childhood Obesity
Current Hypertension Reviews Lifestyle Modifications in the Treatment of Hypertension
Current Hypertension Reviews Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design